Hepion net loss widens to $1.25 million in Q2 2026; revenue flat at no revenue
Reuters2026/08/13 10:59- Hepion posted a net loss of USD 1.25 million for the quarter ended June 30, 2026, widening from USD 1.04 million.
- Operating loss narrowed to USD 1.21 million from USD 1.75 million, on lower operating expenses of USD 1.21 million.
- General and administrative costs rose to USD 1.16 million from USD 919,488, while research and development spending fell to USD 50,918 from USD 423,277.
- No revenue was reported, while a USD 42,989 warrant fair-value loss replaced a USD 698,073 gain a year earlier.
- Strategy shifted toward diagnostics, including a Cirna Diagnostics license with USD 70,000 paid upfront and potential milestones up to USD 6.85 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ivy League’s space gamble: Harvard reveals $2.2 billions SpaceX position, its largest single stock holding
Harvard University Investment Management Company disclosed that it holds $2.2 billion worth of SpaceX shares, making it the largest single stock position in its $4.3 billion US equity portfolio. This holding originated from Harvard’s early investment in SpaceX through venture capital funds, and the position has significantly appreciated after SpaceX’s public listing in June this year. The University of California also disclosed a roughly $1 billion position in SpaceX during the same period. Over the past decade, endowment funds from several universities have made substantial bets on private tech assets.
Circle obtains Major Payment Institution license in Singapore
Crypto prices
More
